关键词：生物仿制药；生长激素；促红细胞生成素；白细胞介素；胰岛素
摘 要：Biosimilars are defined as the follow-on versions of original biological medicines. These are separately developed after the patent protecting the original product has expired. Biosimilar medicines are intended to have the same mechanism of action as original biological medicines, and are designed to treat the same diseases as the innovator’s product. However, biosimilars have many similarities, but are not identical to the reference biopharmaceutical product. This is mainly because the nature of the manufacturing process and the size and complexity of the active substances in biosimilars differ from the generic chemical products.
目 录：

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

03.1 Market Overview

03.2 Product Offerings

04. Market Research Methodology

04.1 Market Research Process

04.2 Research Methodology

05. Introduction

06. Market Landscape

06.1 Market Overview

06.2 Market Size and Forecast

06.3 Biosimilars Market in the US

06.3.1 Market Size and Forecast

06.4 Biosimilars Market in Europe

06.4.1 Market Size and Forecast

06.5 Biosimilars Market in Japan

06.5.1 Market Size and Forecast

06.6 Biosimilars Market in India

06.6.1 Market Size and Forecast

06.7 Biosimilars Market in China

06.7.1 Market Size and Forecast

06.8 Five Forces Analysis

07. Market Segmentation by Application

08. Geographical Segmentation

08.1 Biosimilars Market in the APAC Region

08.1.1 Market Size and Forecast

08.2 Biosimilars Market in the EMEA Region

08.2.1 Market Size and Forecast

08.3 Biosimilars Market in the Americas

08.3.1 Market Size and Forecast

09. Buying Criteria

10. Market Growth Drivers

11. Drivers and their Impact

12. Market Challenges

13. Impact of Drivers and Challenges

14. Market Trends

15. Trends and their Impact

16. Vendor Landscape

16.1 Competitive Scenario

16.1.1 Key News

16.1.2 Mergers and Acquisitions

16.2 Market Share Analysis 2013

16.3 Other Prominent Vendors

16.3.1 Competitive Analysis in the US

16.3.2 Competitive Analysis in Europe

16.3.3 Competitive Analysis in Japan

16.3.4 Competitive Analysis in India

16.3.5 Competitive Analysis in China

17. Patent Expiries

18. Key Vendor Analysis

18.1 Biocon Ltd.

18.1.1 Business Overview

18.1.2 Business Segmentation

18.1.3 Key Information

18.1.4 SWOT Analysis

18.2 Celltrion Inc

18.2.1 Business Overview

18.2.2 Key Information

18.2.3 SWOT Analysis

18.3 Dr. Reddy's Laboratories Ltd.

18.3.1 Business Overview

18.3.2 Business Segmentation

18.3.3 Key Information

18.3.4 SWOT Analysis

18.4 F. Hoffmann-La Roche Ltd.

18.4.1 Business Overview

18.4.2 Business Segmentation

18.4.3 Key Information

18.4.4 SWOT Analysis

18.5 Hospira Inc.

18.5.1 Business Overview

18.5.2 Business Segmentation

18.5.3 Key Information

18.5.4 SWOT Analysis

18.6 Intas Pharmaceuticals Ltd.

18.6.1 Business Overview

18.6.2 Key Information

18.6.3 SWOT Analysis

18.7 Mylan Inc.

18.7.1 Business Overview

18.7.2 Business Segmentation

18.7.3 Key Information

18.7.4 SWOT Analysis

18.8 Novartis AG

18.8.1 Business Overview

18.8.2 Business Segmentation

18.8.3 Key Information

18.8.4 SWOT Analysis

18.9 Teva Pharmaceutical Industries Ltd.

18.9.1 Business Overview

18.9.2 Business Segmentation

18.9.3 Key Information

18.9.4 SWOT Analysis

18.11 3SBio Inc.

18.11.1 Business Overview

18.11.2 Key Information

18.11.3 SWOT Analysis

19. Other Reports in this Series